Only 0.3% of FDA-cleared radiology AI devices have registered trials on patient outcomes, raising concerns about evidence standards.
Key Details
- 11,059 FDA-cleared AI devices are used in radiology; only three had registered trials on patient outcomes.
- 2Out of 1,357 total FDA-cleared AI medical devices, just three evaluated mortality, morbidity, or readmissions.
- 3Only 2.5% were linked to prospective trials, 0.9% posted results or had peer-reviewed publications.
- 462% of studies used small, homogeneous cohorts; vulnerable populations often excluded (e.g., pregnant, pediatric, non-English speakers).
- 5Authors recommend a three-phase evidence ladder with mandatory demographic reporting and larger, prospective trials.
- 6FDA's 510(k) pathway only requires substantial equivalency, not proof of clinical benefit to patients.
Why It Matters
This report highlights a significant gap between regulatory clearance and actual clinical outcome testing for radiology AI, calling attention to the need for stronger pre- and post-market evidence requirements and greater transparency. Radiology professionals and purchasers should scrutinize the clinical validation of AI tools before adoption.

Source
AuntMinnie
Related News

•AuntMinnie
Deep Learning PET Biomarkers Outperform Clinical Tools in Prostate Cancer Survival Prediction
Deep learning-derived PET biomarkers more accurately predict metastatic prostate cancer survival than standard clinical risk models.

•AuntMinnie
Multinational AI Model Flags Osteoporosis on Chest X-rays
AI can opportunistically detect osteoporosis from chest x-rays across diverse international populations.

•AuntMinnie
Two-Stage LLM Pipeline Boosts Patient-Friendly Radiology Reports
A two-stage LLM process significantly improves the readability and accuracy of radiology reports for patients.